Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

    Best Selling Products

    BioNewsCast Press Release Distribution Service

    BioNewsCast Press Release Distribution Service

     

    3rd Annual Stability Testing Conference

    3rd Annual Stability Testing Conference

     

    Next-Gen Sequencing Trends 2009

    Next-Gen Sequencing Trends 2009

     

    Competitor Analysis: c-MET/HGF Inhibitors

    Competitor Analysis: c-MET/HGF Inhibitors

     

    The Japanese Pharmaceutical Market 2008-2023

    The Japanese Pharmaceutical Market 2008-2023

     

    New Products

    Japanese Pharmaceutical Market 2009-2024

    Japanese Pharmaceutical Market 2009-2024

     

    3rd Annual Lyophilisation Conference

    3rd Annual Lyophilisation Conference

     

    The Global Bioinformatics Market: Market size, forecasts and company profiles

    The Global Bioinformatics Market: Market size, forecasts and company profiles

     

    Pharmaceutical Mergers and Acquisitions (PH133)

    Pharmaceutical Mergers and Acquisitions (PH133)

     

    Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

    Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

     

    Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

    Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

     

    The Global Analgesics Market 2009-2024

    The Global Analgesics Market 2009-2024

     

    Competitor Analysis: Coagulation Factors

    Competitor Analysis: Coagulation Factors

     

    Competitor Analysis: PDGF-R Agonists and Antagonists

    Competitor Analysis: PDGF-R Agonists and Antagonists

     

    World Market for Addiction Disorders, 2009-2016

    World Market for Addiction Disorders, 2009-2016

     

    BioPortfolio | Jain PharmaBiotech Reports |  Proteomics - Technologies, Markets and Companies

    Proteomics - Technologies, Markets and Companies

    Proteomics - Technologies, Markets and Companies


    This report describes and evaluates the proteomic technologies that will play an important role in drug discovery, molecular diagnostics and practice of medicine in the post-genomic era - the first decade of the 21st century. Most commonly used technologies are 2D gel electrophoresis for protein separation and analysis of proteins by mass spectrometry. Microanalytical protein characterization with multidimentional liquid chromatography/mass spectrometry improves the throughput and reliability of peptide mapping. Matrix-Assisted Laser Desorption Mass Spectrometry (MALDI-MS) has become a widely used method for determination of biomolecules including peptides, proteins. Functional proteomics technologies include yeast two-hybrid system for studying protein- protein interactions. Establishing a proteomics platform in the industrial setting initially requires implementation of a series of robotic systems to allow a high-throughput approach for analysis and identification of differences observed on 2D electrophoresis gels. Protein chips are also proving to be useful. Proteomic technologies are now being integrated into the drug discovery process as complimentary to genomic approaches. Toxicoproteomics, i.e. the evaluation of protein expression for understanding of toxic events, is an important application of proteomics in preclincial drug safety. Use of bioinformatics is essential for analyzing the massive amount of data generated from both genomics and proteomics.

    Proteomics is providing a better understanding of pathomechanisms of human diseases. Analysis of different levels of gene expression in healthy and diseased tissues by proteomic approaches is as important as the detection of mutations and polymorphisms at the genomic level and may be of more value in designing a rational therapy. Protein distribution / characterization in body tissues and fluids, in health as well as in disease, is the basis of the use of proteomic technologies for molecular diagnostics. Proteomics will play an important role in medicine of the future which will be personalized and will combine diagnostics with therapeutics.The text is supplemented with 42 tables, 27 figures and over 500 selected references from the literature.

    The number of companies involved in proteomics has increased remarkably during the past few years. More than 300 companies have been identified to be involved in proteomics and 226 of these are profiled in the report with 454 collaborations.

    The markets for proteomic technologies are difficult to estimate as they are not distinct but overlap with those of genomics, gene expression, high throughput screening, drug discovery and molecular diagnostics. Markets for proteomic technologies are analyzed for the year 2007 and are projected to years 2012 and 2017. The largest expansion will be in bioinformatics and protein biochip technologies. Important areas of application are cancer and neurological disorders

    Table of contents

    Part I: Technologies and Markets

    Basics of Proteomics

    Proteomic Technologies

    Protein Biochip technology

    Bioinformatics in Relation to Proteomics

    Research in Proteomics

    Pharmaceutical Applications of Proteomics

    Application of Proteomics in Healthcare

    Commercial Aspects of Proteomics

    Future of Proteomics

    References

    August 2009.. 587 Pages. 42 Tables, 27 Figures, 212 Companies profiled, 474 Alliances listed and 500 References.


    Table of Contents
    Full Table of Contents (DOC)

    Price



    BioPortfolio uses RBS Worldpay Secure Server for credit card transactions